Globally there are various players operating in this market. The Americas and Europe are hubs for major companies, generating maximum market share which has turned these regions into well-established markets. These companies have expanded their operating units in various other regions as well. Moreover, there are numerous small and medium scale players that generate maximum revenue from local markets.
The above diagram displays the market share of major companies operating in the global anticholinergic drugs market. The global anticholinergic drugs market is led by Boehringer Ingelheim International GmbH (Germany) with 21.2% of the global market share followed by GlaxoSmithKline plc (UK) with 16.6%, and Astellas Pharma Inc. (Japan) with 12.8% of the market share.
Boehringer Ingelheim International GmbH (Germany) is one of the leading players in the field of anticholinergic drugs. The firm accounted for 21.8% share in 2017. The company provides innovative anticholinergic drugs by strengthening research and development activities. It offers Atrovent, Atrovent HFA, Spiriva, Combivent Respimat well-known anticholinergic drugs portfolio. It is focused on organic strategies to maintain its leading position in the global market. Recently, in September 2015 the company received the FDA approval new indication for Spiriva Respimat. Similarly, in May 2015 the company received FDA approval for Stiolto Respimat Inhalation Spray.
GlaxoSmithKline plc (UK) contributes to approximately 16.6% of the global anticholinergic drugs market. It offers Incruse Ellipta and Trelegy Ellipta major brand in the anticholinergic drugs market. The company focuses on research and development activities to introduce innovative products in the market to maintain its position in the global market. The firm has a presence across the world that enhances its market share.
Astellas Pharma Inc. (Japan) accounted for the third largest spot with 12.8% of the market share. The company develops and offers a wide range of anticholinergic drug products in the market. The company focused on organic growth strategies to maintain its position in global market. Recently, in January 2016 the company launched Vesicare in Algeria market.
Bargaining Power of Suppliers
The suppliers in the anticholinergic drugs industry are the developers and manufacturers of anticholinergic drugs. Currently, a large number of suppliers are present in the market due to the rising application of anticholinergic drugs and the strong presence of an already established player. However, few existing key companies capture significant share in the global market and have the capability of fluctuating the costs of the drugs. Switching cost of these suppliers is medium because suppliers tend to enter into long-term associations, partnership, and deals with the other drug manufacturing companies. The overall bargaining power of suppliers in the global anticholinergic drugs market is high.
Bargaining Power of Buyers
The bargaining power of the buyers is medium to high in the global anticholinergic drugs market due to the presence of a huge number of buyers in the industry. Considering the urbanization and rising older population the market for anticholinergic drugs is identified to have a high and significant customer base. However, the buyers tend to use the products that have been provided by the top players irrespective of the pricing, which affects the power of a buyer in the industry.
Threat of New Entrants
The threat of new entrants is high in the global anticholinergic drugs market due to developing the potential market. Any manufacturing company trying to enter the market is required to accept the mandatory regulatory standards issued by government authorities. Moreover, advancements in the industry are more likely to attract new companies to enter the business. The rise in the demand for advanced anticholinergic drugs in the coming future is expected to attract the currently established and other manufacturers to focus more on this segment. There is a stronghold of the big companies in the Middle East market, which can make the entry of the new players a bit difficult.
Threat of Substitutes
The threat of substitutes in the global anticholinergic drugs market is medium to high because of the presence of laxatives. But, quality and trust issue and excellent service provided by the existing players restrict the threat by the substitutes. Also, the low-medium degree of switching cost may minimize the threat of substitutes.
Intensity of Rivalry
The degree of competition in the anticholinergic drugs market is high. Differentiation among existing players and the introduction of the newer products is increasing the intensity of rivalry in the market. Anticholinergic drugs manufacturing companies are trying to develop products of high quality and enhanced safety to increase the demand for these products in developed countries and developing regions. To overcome the competition, players are engaged in partnering with established organizations and welcoming tie-ups. Moreover, the players are also developing advanced products for differentiating their brand from competitors.
